Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745013 | 1.00 | TSHR (0.50) | TSHRADORA1CD44SLC6A2SLC6A4 | |
| SCHEMBL31686161 | 0.89 | TSHR (0.50) | TSHRADORA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26643886 | 0.89 | TSHR (0.50) | TSHRADORA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21496827 | 0.87 | TSHR (0.54) | TSHRALDH1A1HSD17B10CLEC4MCDC25B | |
| Hydrochloric Acid SCHEMBL21496725 | 0.86 | TSHR (0.53) | TSHRALDH1A1HSD17B10CLEC4MCDC25B | |
| SCHEMBL2355554 | 0.84 | CD44 (0.49) | TSHRCD44ALDH1A1HSD17B10 | |
| SCHEMBL29609011 | 0.84 | CD44 (0.49) | TSHRCD44ALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL4438179 | 0.83 | CD44 (0.47) | TSHRCD44ALDH1A1HSD17B10 | |
| SCHEMBL7276418 | 0.80 | TSHR (0.56) | TSHRALDH1A1HSD17B10CLEC4MCDC25B | |
| SCHEMBL10642313 | 0.78 | KDM4E (0.45) | TSHRADORA1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3704113-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| CN-111295382-A | Bridged bicyclic compounds as modulators of farnesoid X receptors | 百时美施贵宝公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | TSHR 925/4885ADORA1 736/4885CD44 2845/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | TSHR 925/4885ADORA1 736/4885CD44 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.